AE of tofacitinib and glucocorticoid during the 24-week period.
malignancy, DVT, malignant tumors, cytopenia, Cancer
PULMONARY EMBOLISM, RECURRENCE, DEEP VEIN THROMBOSIS, DVT, MALIGNANT TUMORS, ADVERSE EVENT, CYTOPENIA, CANCER
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DVT, deep vein thrombosis; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PE, pulmonary embolism; SAE, severe adverse event; TC, total cholesterol; TG, triglyceride; ULN, upper limit of normal.Cancer: new malignancy or patients with malignant tumors who have been successfully treated for more than 5 years before screening, recent recurrence; cytopenia: Hb <90 g/L, or neutrophil <1 × 10